Portal de investigación
Advances and controversies in management of breast ductal carcinoma in situ (DCIS).
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Farante G
- Toesca A
- Magnoni F
- Lissidini G
- Mastropasqua M
- Viale G
- Penco S
- Cassano E
- Lazzeroni M
- Bonanni B
- Leonardi MC
- Curigliano G
- Orecchia R
- Galimberti V
- Veronesi P
Grupos
Abstract
Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer. It accounts for 25% of all breast cancers diagnosed, as a result of the expansion of breast cancer screening and is associated with a high survival rate. DCIS is particularly clinically challenging, due to its heterogeneous pathological and biological traits and its management is continually evolving towards more personalized and less aggressive therapies. This article suggests evidence-based guidelines for proper DCIS clinical management, which should be discussed within a multidisciplinary team in order to propose the most suitable approach in clinical practice, taking into account recent scientific studies. Here we include updated multidisciplinary treatment protocols and techniques in accordance with the most recent contributions published on this topic in the peer-reviewed medical literature, and we outline future perspectives.
Copyright © 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0748-7983, 1532-2157
- Tipo:
- Article
- Páginas:
- 736-741
- Factor de Impacto:
- 1,016 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
EJSO ELSEVIER SCI LTD
Citas Recibidas en Web of Science: 13
Documentos
- No hay documentos
Filiaciones
Keywords
- Breast cancer, Ductal carcinoma in situ, Guidelines, Medical treatment, Radiotherapy, Surgery
Campos de estudio
Proyectos asociados
ESTUDIO SIMPLE CIEGO, ALEATORIZADO, MULTICÉNTRICO, CON CONTROL ACTIVO PARA EVALUAR LA SEGURIDAD, TOLERABILIDAD, FARMACOCINÉTICA Y EFICACIA DE CEFTAZIDIMA Y AVIBACTAM CUANDO SE PROPORCIONAN CON METRONIDAZOL EN COMPARACIÓN CON MEROPENEM EN NIÑOS DE 3 MESES A MENOS DE 18 AÑOS DE EDAD CON INFECCIONES INTRAABDOMINALES COMPLICADAS (IIACS).
Investigador Principal: EMILIO MONTEAGUDO MONTESINOS
D4280C00015 . 2015
ESTUDIO PARA LA VALIDACIÓN DEL VALOR PRONÓSTICO DE LA CARGA TUMORAL TOTAL, DETERMINADO POR OSNA, DE LA METÁSTASIS EN EL GANGLIO CENTINELA DEL CÁNCER DE MAMA.
Investigador Principal: FRANCISCO RIPOLL ORTS
GES-2017-01 . 2018
CHAIMELEON. ACCELERATING THE LAB TO MARKET TRANSITION OF AI TOOLS FOR CANCER MANAGEMENT.
Investigador Principal: LUIS MARTÍ BONMATÍ
952172 . COMISION EUROPEA . 2020
EVALUACIÓN DE LA SEGURIDAD DE LA ESTIMULACIÓN OVÁRICA CONTROLADA COMO TÉCNICA DE PRESERVACIÓN DE LA FERTILIDAD EN PAC IENTES CON CÁNCER DE MAMA.
Investigador Principal: CÉSAR DÍAZ GARCÍA
ISF-LET-2019-01 . 2020
UTILIZACIÓN DE LA RADIOTERAPIA INTRAOPERATORIA EN LA NEOPLASIA DE MAMA.
Investigador Principal: FRANCISCO JAVIER CELADA ÁLVAREZ
SESPM-19-1 . 2021
Cita
Farante G,Toesca A,Magnoni F,Lissidini G,Vila J,Mastropasqua M,Viale G,Penco S,Cassano E,Lazzeroni M,Bonanni B,Leonardi MC,Ripoll F,Curigliano G,Orecchia R,Galimberti V,Veronesi P. Advances and controversies in management of breast ductal carcinoma in situ (DCIS). Eur J Surg Oncol. 2022. 48. (4):p. 736-741. IF:3,800. (1).